GSK wins legal case over withdrawal effects of paroxetine after 13 years and £9.33m in costsBMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2799 (Published 10 July 2020) Cite this as: BMJ 2020;370:m2799
- Clare Dyer
- The BMJ
A group action in the High Court in London by scores of claimants over withdrawal problems with the antidepressant paroxetine has ended in a victory for the manufacturer, GlaxoSmithKline (GSK), 13 years after the case was first launched.1
A High Court trial was to start in February 2011 but the action was put on hold after legal aid was withdrawn and 369 claimants dropped their cases. In 2015 the litigation was revived when the remaining 124 claimants instructed new solicitors and found commercial funding.
In 2016 GSK asked the court to bring the case to a permanent halt, but Mr Justice Foskett said he wanted to see how the case progressed in stages before deciding if it should be stopped or go to trial.2
From the beginning, the claimants’ case had been that paroxetine, a selective serotonin reuptake inhibitor (SSRI) known …